Join Clinical Trials in California for Cancer

All Categories Most Often Searched » Cancer » California

Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2012
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Mitoxantrone; Drug: Prednisone; Drug: Pegfilgrastim
Sponsors: University of California, San Francisco; Andrea Harzstark; Sanofi-Aventis
Not yet recruiting - verified May 2012
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: PLX3397; Drug: Eribulin
Sponsors: University of California, San Francisco; Hope Rugo, MD; Susan G. Komen Breast Cancer Foundation; Plexxikon, Inc.; Eisai Inc.
Not yet recruiting - verified May 2012
Double Cord vs. Haploidentical (BMT CTN #1101)

Conditions: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Burkitt's Lymphoma; Follicular Lymphoma; Hodgkin Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: Biological/Vaccine: Haploidentical BMT; Drug: Double Cord Blood Transplantation
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Conditions: Myeloid Malignancy; Bone Marrow Failure Syndrome; Transfusion-dependent Red Blood Cell (RBC) Defect; Congenital Immunodeficiency; Metabolic Disease; Severe Immune Dysregulation
Interventions: Drug: Alemtuzumab; Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine
Sponsors: University of California, San Francisco; Christopher Dvorak
Not yet recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Anaplastic Large Cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Isolated Plasmacytoma of Bone; Monoclonal Gammopathy of Undetermined Significance; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Hodgkin Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Multiple Myeloma; Stage I Small Lymphocytic Lymphoma; Stage IA Mycosis Fungoides/Sezary Syndrome; Stage IB Mycosis Fungoides/Sezary Syndrome; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage IIA Mycosis Fungoides/Sezary Syndrome; Stage IIB Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IIIA Mycosis Fungoides/Sezary Syndrome; Stage IIIB Mycosis Fungoides/Sezary Syndrome; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Small Lymphocytic Lymphoma; Stage IVA Mycosis Fungoides/Sezary Syndrome; Stage IVB Mycosis Fungoides/Sezary Syndrome; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Condition: Newly Diagnosed Glioblastoma Multiforme
Intervention: Other: Lapatinib/Temozolomide/radiation
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
Acceptance-Based Treatment for Prostate Cancer Distress

Condition: Early Stage Prostate Cancer
Intervention: Behavioral: Acceptance and Commitment Therapy
Sponsors: Veterans Medical Research Foundation; Veterans Medical Research Foundation; Alliant International University; University of California, San Diego
Recruiting - verified April 2012
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

Condition: Cancer of Head and Neck
Intervention: Biological: GL-ONC1
Sponsors: Genelux Corporation; Genelux Corporation
Recruiting - verified April 2012
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii Cancer Research Center; University of Vermont
Not yet recruiting - verified April 2012
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Condition: Malignant Melanoma
Intervention: Drug: Zelboraf (vemurafenib)
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Not yet recruiting - verified April 2012
National Breast Cancer and Lymphedema Registry

Conditions: Breast Cancer; Lymphedema
Intervention:
Sponsors: Stanford University; Stanley Rockson
Recruiting - verified April 2012
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012
Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Study in Recurrent Glioblastoma (GB)

Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Condition: Head and Neck Cancer
Interventions: Drug: MEHD7945A; Drug: cetuximab
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Condition: Neuroblastoma
Interventions: Radiation: 124I-MIBG (no-carrier added); Radiation: 124I-MIBG (carrier added)
Sponsors: University of California, San Francisco; Katherine Matthay
Not yet recruiting - verified April 2012
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Conditions: Leukemia; Lymphoma; Small Intestine Cancer
Interventions: Drug: alisertib; Drug: vorinostat; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network

Conditions: Non-small Cell Lung Cancer Metastatic; Small Cell Lung Carcinoma
Intervention: Other: therapeutic interventions
Sponsors: Vanderbilt-Ingram Cancer Center; David P. Carbone, M.D. PhD; Addario Lung Cancer Institute (ALCMI)
Recruiting - verified April 2012
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Biological: autologous dendritic cell adenovirus CCL21 vaccine
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012
Assessment of Patient Experience During Treatment for Cancer

Condition: Carcinoma
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Conditions: Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Sponsors: University of California, San Francisco; University of California, San Francisco; Eisai Inc.
Not yet recruiting - verified March 2012
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer

Condition: Cervical Cancer
Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Cisplatin
Sponsors: University of California, San Diego; University of California, San Diego; National Cancer Institute (NCI)
Recruiting - verified March 2012
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study

Condition: Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified March 2012
Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers

Conditions: Stage 4 Stomach/Gastric Cancer; Patients and Caregivers
Intervention: Behavioral: bulletin board and teleophone depth interview
Sponsors: Find A Cure Panel; Find A Cure Panel
Recruiting - verified March 2012
Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers

Condition: Stage 4 Liver Cancer
Interventions: Behavioral: bulletin board or telephone depth interview (TDI); Behavioral: interview regarding experiences and opinions as to condition and treatment
Sponsors: Find A Cure Panel; Find A Cure Panel
Recruiting - verified March 2012
Cancer Symptom Data From Multiple Treatment Centers

Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas

Conditions: Basal Cell Nevus Syndrome; Gorlin's Syndrome
Interventions: Drug: GDC-0449; Procedure: Aminolevulinic acid %20 topical solution + blue light
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; Genentech
Recruiting - verified May 2012
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

Condition: Cervical Carcinoma
Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT); Drug: Cisplatin; Drug: Gemcitabine
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified March 2012
A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function

Condition: Solid Cancers
Intervention: Drug: Vismodegib
Sponsors: Genentech; Genentech
Not yet recruiting - verified March 2012
A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Carfilzomib
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium; Novartis; Onyx Therapeutics, Inc.
Recruiting - verified March 2012
Targeted Intraoperative Radiotherapy United States (TARGIT-US) Registry Trial

Conditions: Malignant Neoplasm of Breast; Breast Radiotherapy; Breast Diseases; Ductal Breast Carcinoma; Intraoperative Radiotherapy
Intervention: Radiation: Intraoperative radiation therapy (IORT)
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute; Northwestern University; Los Angeles Women's Health Clinic of California Hospital and Medical Center
Not yet recruiting - verified April 2012
Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer

Condition: Cervical Cancer
Intervention: Other: Blood draw
Sponsors: Stanford University; Stanford University
Recruiting - verified March 2012
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Condition: Early Stage Breast Cancer
Intervention: Drug: Denosumab
Sponsors: University of California, San Francisco; Hope Rugo, MD; University of California, San Francisco; Amgen
Not yet recruiting - verified March 2012
Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy

Condition: Stage, Breast Cancer
Interventions: Behavioral: Brief behavioral treatment for insomnia and bright light; Behavioral: treatment as usual
Sponsors: University of California, San Diego; University of California, San Diego
Not yet recruiting - verified February 2012
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Condition: Glioblastoma, Glioma
Intervention: Drug: GDC-0084
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Condition: Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer

Condition: Bone Cancer
Interventions: Radiation: fluorine F 18 sodium fluoride; Procedure: positron emission tomography/computed tomography
Sponsors: Stanford University; Stanford University
Not yet recruiting - verified February 2012
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Condition: Prostatic Neoplasm
Intervention: Radiation: radiation therapy
Sponsors: Sharp Memorial Hospital; Sharp Memorial Hospital
Recruiting - verified March 2012
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Conditions: Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: trebananib; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors

Condition: Younger Breast Cancer Survivors
Intervention: Behavioral: Mindful Awareness practices (MAPs)
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified March 2012
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Condition: Metastatic Solid Tumors
Intervention: Drug: PZP115891, PCI-24781
Sponsors: University of California, San Francisco; Pamela Munster; GlaxoSmithKline; Pharmacyclics
Not yet recruiting - verified February 2012
Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors

Condition: Breast Cancer
Intervention: Behavioral: Improving Cognition with group intervention
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center; Breast Cancer Research Foundation
Recruiting - verified April 2012
FdCyd and THU for Advanced Solid Tumors

Condition: Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine; Drug: Tetrahydrouridine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified February 2012
Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer

Condition: Recurrent Renal Cell Cancer
Interventions: Procedure: robot-assisted laparoscopic surgery; Procedure: robot-assisted laparoscopic surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Vismodegib for Treatment of Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib; Drug: Placebo
Sponsors: Loma Linda University; Loma Linda University
Not yet recruiting - verified April 2012
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Ipilimumab and GM-CSF
Sponsors: University of California, San Francisco; University of California, San Francisco; Bristol-Myers Squibb; Genzyme
Not yet recruiting - verified February 2012
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: talactoferrin; Other: laboratory biomarker analysis
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)

Condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Intervention: Drug: CO-1686
Sponsors: Clovis Oncology, Inc.; Clovis Oncology, Inc.
Recruiting - verified March 2012
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Condition: Advanced, Incurable Solid Tumors
Interventions: Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel; Drug: PLX3397 + Paclitaxel
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Conditions: Inflammatory Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

Condition: Colon Cancer
Intervention: Drug: PDT with 5-ALA radiosensitization
Sponsors: Holcombe, Randall F., M.D.; Holcombe, Randall F., M.D.; University of California, Irvine; National Cancer Institute (NCI)
Recruiting - verified January 2012
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Intervention: Biological: therapeutic allogeneic lymphocytes
Sponsors: Stanford University; Robert Lowsky; National Cancer Institute (NCI)
Recruiting - verified February 2012
Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 chloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified April 2012
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Condition: Metastatic Breast Cancer
Interventions: Biological: OPT-822/OPT-821; Biological: Phosphate Buffer Saline (PBS)
Sponsors: Optimer Pharmaceuticals; Optimer Biotechnology, Inc.
Recruiting - verified January 2012
The Gastric Cancer Foundation: A Gastric Cancer Registry

Condition: Gastric Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy

Condition: Epithelial Ovarian Cancer
Interventions: Biological: Placebo Study Agent; Biological: Cvac
Sponsors: Prima BioMed Ltd; Prima BioMed Ltd
Recruiting - verified May 2012
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Conditions: Neoplasms; Cancer
Interventions: Drug: VGX-100; Drug: Bevacizumab
Sponsors: Circadian Technologies Ltd.; Circadian Technologies Ltd.
Recruiting - verified March 2012
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Condition: Malignant Melanoma
Intervention: Drug: DEDN6526A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
LIFE Cancer Survivorship Database for Pediatric Cancer

Condition: Pediatric Cancer
Intervention:
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; Beckman Research Institute
Recruiting - verified January 2012
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Conditions: Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206; Drug: Doxorubicin
Sponsors: CytRx; CytRx
Recruiting - verified March 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: TPI 287; Drug: Temozolomide; Drug: Irinotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Archer Biosciences, Inc.
Recruiting - verified April 2012
Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Condition: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Intervention: Drug: GRN1005
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified April 2012
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab; Drug: Placebo; Drug: paclitaxel; Drug: cisplatin/carboplatin
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5490258; Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: Placebo; Drug: cisplatin/carboplatin; Drug: paclitaxel
Sponsors: Genentech; Genentech
Not yet recruiting - verified January 2012
Phase I Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Conditions: Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: dovitinib lactate
Sponsors: Stanford University; Heather Wakelee; National Cancer Institute (NCI); Novartis
Not yet recruiting - verified January 2012
Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer

Conditions: Solid Tumors; Prostate Cancer
Intervention: Drug: ADI-PEG 20
Sponsors: Polaris Group; Polaris Group
Recruiting - verified December 2011
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

Conditions: Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Malignant Tumor of Peritoneum; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Radiation: stereotactic body radiation therapy; Procedure: positron emission tomography; Procedure: computed tomography; Other: questionnaire administration; Radiation: fludeoxyglucose F 18
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
Trial of pIL-12 Electroporation Malignant Melanoma

Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12; Device: Intratumoral Electroporation
Sponsors: University of California, San Francisco; University of California, San Francisco; OncoSec Medical Incorporated
Recruiting - verified April 2012
Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting

Conditions: Childhood Acute Lymphoblastic Leukemia; Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies; Ewing Sarcoma; Vomiting in Infants and/or Children; Osteosarcoma
Interventions: Procedure: electroacupuncture therapy; Other: questionnaire administration; Procedure: electroacupuncture therapy
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Conditions: Cancer Survivor; Human Papilloma Virus Infection
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: questionnaire administration; Other: laboratory biomarker analysis; Other: survey administration; Other: medical chart review
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Condition: BRAF Mutant Metastatic Melanoma
Intervention: Drug: BKM120 Combined with Vemurafenib (PLX4032)
Sponsors: University of California, San Francisco; University of California, San Francisco; Novartis
Not yet recruiting - verified January 2012
Quantitative Subharmonic Breast Imaging

Condition: Breast Cancer
Intervention: Other: 3D HI and SHI of ultrasound contrast agent
Sponsors: Thomas Jefferson University; Thomas Jefferson University; National Cancer Institute (NCI); Lantheus Medical Imaging; University of California, San Diego
Recruiting - verified December 2011
Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Conditions: Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T; Drug: abiraterone acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Efficacy & Safety Study of MORAb-004 to Treat Metastatic Colorectal Cancer

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Integrative Approaches for Cancer Survivorship

Condition: Breast Cancer
Intervention: Behavioral: Individualized manualized Ayurvedic intervention
Sponsors: University of California, San Francisco; University of California, San Francisco; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2012
Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Condition: Prostate Cancer
Interventions: Drug: GDC-0068; Drug: GDC-0980; Drug: placebo; Drug: abiraterone; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2012
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Condition: Ovarian Epithelial Carcinoma
Intervention: Drug: PD0332991
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified March 2012
Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Intervention: Drug: Apricoxib
Sponsors: Jonsson Comprehensive Cancer Center; Jonsson Comprehensive Cancer Center
Recruiting - verified March 2012
Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery

Condition: Prostate Cancer
Interventions: Procedure: ultrasound imaging; Procedure: robot-assisted laparoscopic surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Condition: Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions: Drug: MEDI-573 (1 of 2 doses); Drug: Sorafenib
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012
Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: Oral azacitidine plus Abraxane; Drug: Carboplatin; Drug: Abraxane
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2012
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Intervention: Drug: TPI 287
Sponsors: Van Andel Research Institute; Giselle Sholler; Van Andel Research Institute; Archer Biosciences, Inc.
Recruiting - verified April 2012
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified March 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer

Condition: Castration Resistant Prostate Cancer
Intervention: Drug: NRX 194204
Sponsors: Io Therapeutics; Io Therapeutics
Recruiting - verified February 2012
Vitamin D and Breast Cancer in Obesity: Therapeutic Trials

Condition: Breast Cancer
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Stanford University; Robert Carlson
Recruiting - verified December 2011
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of BMS-663513 in Subjects With Advanced and/or Metastatic Solid Tumors

Condition: Cancer - Solid Tumors
Interventions: Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137); Drug: BMS-663513 (Anti-CD137)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers

Condition: Melanoma, Skin
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Not yet recruiting - verified November 2011
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Condition: Follicular Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide; Drug: Rituximab-CHOP; Drug: Rituximab-CVP; Drug: Rituximab-Bendamustine
Sponsors: Celgene Corporation; Celgene Corporation; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified May 2012
Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified January 2012
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Conditions: Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabazitaxel; Drug: prednisone; Drug: octreotide pamoate; Other: questionnaire administration; Drug: octreotide acetate
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Sanofi-Aventis
Not yet recruiting - verified May 2012
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

Condition: Colorectal Cancer, Metastatic
Interventions: Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay; Other: Standard of care
Sponsors: Myriad Genetic Laboratories, Inc.; Myriad Genetic Laboratories, Inc.
Recruiting - verified February 2012
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011
A Study of LY3007113 in Patients With Advanced Cancer

Condition: Metastatic Cancer
Intervention: Drug: LY3007113
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Metastatic Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer

Condition: Basal Cell Carcinomas
Intervention: Device: PulseCure pulse generator and Derm-pulse electrode
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland
Recruiting - verified October 2011
Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (SABR)

Condition: Lung Cancer
Interventions: Procedure: PET Scan; Procedure: CT Scan; Procedure: SABR
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Condition: Rectal Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified November 2011
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012
BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Eribulin; Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Phase 1 Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma

Conditions: Lymphoma; Waldenstrom's Macroglobulinemia; Nonhematologic Malignancies
Interventions: Drug: MLN9708 Capsule B formulation; Drug: MLN9708 Capsule A or B formulation; Drug: MLN9708 Capsule B formulation
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Condition: Neoplasm Malignant
Interventions: Drug: Iniparib (SAR240550-BSI-201); Drug: Gemcitabine; Drug: Carboplatin; Drug: Placlitaxel; Drug: Pegylated liposomal doxorubicin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Other: educational intervention; Other: questionnaire administration; Other: counseling intervention; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: MM-121 (SAR256212) + Paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012
Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

Condition: Low Grade Glioma
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Merck
Recruiting - verified October 2011
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Stanford University; Stanford University; Novartis
Recruiting - verified February 2012
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
Study of Itraconazole in Castration Resistant Prostate Cancer (CRPC) Post Docetaxel Chemotherapy

Conditions: Prostate Cancer; Metastatic Disease
Intervention: Drug: Itraconazole
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

Conditions: Advanced Malignancies; Carcinoma, Non-Small-Cell Lung; Anaplastic Large Cell Lymphoma; Diffuse Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified April 2012
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

Condition: Melanoma
Interventions: Drug: Ipilimumab; Radiation: Radiation Therapy
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System

Condition: Human Papilloma Virus Infection
Intervention:
Sponsors: Gen-Probe, Incorporated; Gen-Probe, Incorporated
Not yet recruiting - verified October 2011
Expressed Prostatic Secretion and Post Massage Urine Biomarkers in Predicting Biopsy Results in Patients Undergoing Prostate Biopsy

Conditions: Conditions Influencing Health Status; Healthy; Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: transrectal prostate biopsy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Cetuximab; Drug: Taxane
Sponsors: Stanford University; Stanford University; Varian Medical Systems
Recruiting - verified April 2012
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: Bendamustine
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

Conditions: Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene; Biological: electroporation-mediated plasmid DNA vaccine therapy; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Condition: Head and Neck Cancer
Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab; Drug: Carboplatin
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease

Condition: Leptomeningeal Metastases
Interventions: Other: pharmacological study; Drug: methotrexate
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Study of Axitinib in Advanced Carcinoid Tumors

Condition: Carcinoid Tumor
Intervention: Drug: Axitinib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Comprehensive Cancer Network; Pfizer
Recruiting - verified March 2012
Radiation Therapy in Treating Patients With Prostate Cancer

Conditions: Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexual Dysfunction
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Condition: Cancer
Intervention: Behavioral: questionnaire administration followed by cognitive interviews
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Ralph Lauren Center for Cancer Care and Prevention; M.D. Anderson Cancer Center; St. Joseph’s Hospital, Los Angeles; Hektoen Stroger Hospital; University of Miami; National Cancer Institute (NCI); FACITtrans, LLC
Recruiting - verified April 2012
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin; Drug: Doxorubicin
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals; Sarcoma Alliance for Research through Collaboration (SARC)
Recruiting - verified March 2012
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff

Condition: Malignant Neoplasm
Interventions: Procedure: spiritual therapy; Other: questionnaire administration; Other: survey administration; Other: counseling intervention; Other: psychosocial support for caregiver; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: DFRF4539A
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Conditions: Uterine Fibroids; Heavy Uterine Bleeding
Interventions: Drug: placebo; Drug: elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo Cohort 4; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified April 2012
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: Akt inhibitor MK2206; Genetic: mutation analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2011
Patient Controlled Tissue Expansion for Breast Reconstruction

Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Condition: Cachexia
Interventions: Drug: BYM338 active drug; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified April 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884; Drug: AG-013736
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

Conditions: Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity
Interventions: Biological: cetuximab; Biological: panitumumab; Drug: erlotinib hydrochloride; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel; Drug: carboplatin; Drug: vorinostat; Other: placebo; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: protein analysis; Genetic: gene expression analysis; Genetic: proteomic profiling
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Invasive Ductal Breast Carcinoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer
Interventions: Drug: zoledronic acid; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012
Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer

Conditions: Adult Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Compression
Interventions: Procedure: musculoskeletal complications management/prevention; Procedure: bone graft; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Condition: Advanced Gastric Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: AC220; Drug: Cytarabine; Drug: Etoposide; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Ambit Biosciences Corporation
Recruiting - verified September 2011
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)

Condition: Metastatic Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: MEGF0444A; Drug: mFOLFOX6; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008); Drug: fresolimumab (GC1008); Radiation: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; University of California, Los Angeles
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Ph I/II Ipilimumab Vemurafenib Combo

Condition: Melanoma
Interventions: Drug: Ipilimumab (BMS-734016); Biological: Vemurafenib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Roche-Genentech
Recruiting - verified November 2011
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy

Condition: Lung Cancer
Intervention: Device: Implantation of anchored Beacon transponder in the lung
Sponsors: Varian Medical; Varian Medical
Recruiting - verified April 2012
A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2835219
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Recombinant Vaccinia Virus Administered Intravenously Followed by Intratumoral Boosts in Patients With Metastatic, Refractory Colorectal Carcinoma

Conditions: Colorectal Carcinoma; CRC
Interventions: Biological: JX-594; Drug: Irinotecan
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Transgene
Recruiting - verified January 2012
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Pazopanib
Sponsors: Stanford University; Kristen Ganjoo; GlaxoSmithKline
Recruiting - verified December 2011
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Condition: Unresectable Stage III or IV Melanoma
Interventions: Biological: INXN-2001; Drug: INXN-1001
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib; Drug: Pemetrexed, docetaxel or gemcitabine
Sponsors: ArQule; ArQule
Recruiting - verified January 2012
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: placebo
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Condition: Sarcoma, Alveolar Soft Part
Interventions: Drug: Cediranib; Drug: Sunitinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Molecular Analysis of Thoracic Malignancies

Conditions: Thymus Cancer; Thymoma; Thymic Carcinoma; Lung Cancer; Carcinoma, Non-Small-Cell Lung; Mesothelioma
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Conditions: Hepatocellular Carinoma; Liver Cancer; HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF; Other: Best Supportive Care
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Recruiting - verified November 2011
TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

Conditions: Lymphoma, Non-Hodgkin; Cutaneous Lymphoma; Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma; Marginal Zone B-Cell Lymphoma; Peripheral T-cell Lymphoma, Large Cell; Waldenstrom Macroglobulinemia
Interventions: Procedure: CT Scan; Procedure: local radiotherapy; Drug: VTX-2337
Sponsors: Stanford University; Stanford University; VentiRx Pharmaceuticals Inc.
Recruiting - verified July 2011
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Conditions: Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: axitinib; Procedure: therapeutic conventional surgery; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

Conditions: Breast Cancer; Fertility
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Conditions: Recurrent Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder
Interventions: Drug: docetaxel; Drug: lapatinib ditosylate; Other: immunohistochemistry staining method; Genetic: fluorescence in situ hybridization; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
Male Stress Urinary Incontinence and Sexual Health

Condition: Prostate Cancer
Interventions: Device: Artificial urinary sphincter; Device: InVance Sling; Device: AdVance Sling; Device: Virtue Sling; Drug: Contigen
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Conditions: Pancreatic Cancer; Adenocarcinoma; Pancreatic Neoplasms
Intervention: Drug: FOLFIRINOX, IPI-926
Sponsors: University of California, San Francisco; University of California, San Francisco; Infinity Pharmaceuticals, Inc.
Recruiting - verified March 2012
Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance

Condition: Colon Polyp
Interventions: Procedure: Water infusion in lieu of air insufflation; Procedure: Air method
Sponsors: VA Northern California Health Care System; VA Northern California Health Care System
Recruiting - verified July 2011
Combination Trial MSC1936369B With Temsirolimus

Condition: Advanced Solid Tumor
Intervention: Drug: MEK inhibitor MSC1936369B and Temsirolimus
Sponsors: EMD Serono; EMD Serono
Recruiting - verified April 2012
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Condition: Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
Intervention: Drug: RGI-2001
Sponsors: Regimmune Inc.; Regimmune Inc.; Pacific-Link Regulatory Consulting LLC
Recruiting - verified January 2012
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Solid Cancers
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Ovarian Reserve Testing in Female Young Adult Cancer Survivors

Conditions: Cancer; Infertility
Intervention: Drug: recombinant FSH
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified May 2011
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Condition: Lambert Eaton Myasthenic Syndrome
Interventions: Drug: Amifampridine Phosphate; Drug: Placebo
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids

Condition: Uterine Fibroids
Interventions: Procedure: MR Guided Focused Ultrasound; Procedure: Placebo MR Guided Focused Ultrasound
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Conditions: Pheochromocytoma; Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified July 2011
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study

Condition: Prostate Cancer
Intervention:
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012
Nuevo Amanecer: Promoting the Psychosocial Health of Latinas

Conditions: Breast Neoplasms; Psychology, Social
Intervention: Behavioral: Peer Support Program
Sponsors: University of California, San Francisco; University of California, San Francisco; California Breast Cancer Research Program; Circulo de Vida Cancer Support and Resource Center
Recruiting - verified January 2012
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

Condition: Breast Cancer
Interventions: Device: Trident Specimen Radiography System; Device: Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
Sponsors: Levine, Gary M. , M.D.; Levine, Gary M. , M.D.; Hologic, Inc.
Recruiting - verified March 2012
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2

Conditions: Breast Cancer; Non-Small-Cell Lung Cancer; Glioblastoma; Other Cancers
Intervention: Drug: FPPRGD2
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Conditions: Thymoma; Thymus Cancer; Thymic Carcinoma
Intervention: Drug: Amrubicin
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

Condition: Solid Tumour
Intervention: Drug: MFGR1877S
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Condition: Multiple Myeloma
Interventions: Drug: Group A: Carfilzomib & Non-IMiD Regimen; Drug: Group B: Carfilzomib & IMiD containing regimen.
Sponsors: Oncotherapeutics; Oncotherapeutics; Onyx Pharmaceuticals
Recruiting - verified February 2012
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
Safety and PK Study of RRx-001 in Cancer Subjects

Conditions: Malignant Solid Tumor; Lymphomas
Interventions: Drug: RRx-001; Drug: RRx-001; Drug: RRx-001; Drug: RRx-001; Drug: RRx-001; Drug: RRx-001
Sponsors: RadioRx, Inc; RadioRx, Inc
Recruiting - verified January 2012
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Oral palonosetron; Drug: I.V. palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified July 2011
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

Condition: Malignant Melanoma, Metastatic
Interventions: Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF); Biological: Ipilimumab
Sponsors: Northern California Melanoma Center; Lynn E. Spitler, MD; University of California, San Francisco
Recruiting - verified May 2012
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer

Conditions: Pancreaticobiliary Cancers; Jaundice; Bile Duct Obstruction
Interventions: Procedure: ERCP; Procedure: EUS FNA
Sponsors: California Pacific Medical Center Research Institute; California Pacific Medical Center Research Institute
Recruiting - verified May 2011
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Conditions: B Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
Sponsors: Avila Therapeutics; Avila Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified May 2011
Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: PF-04691502; Drug: PD-0325901; Drug: PF-04691502; Drug: irinotecan; Drug: PF-05212384; Drug: irinotecan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Conditions: Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified November 2011
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF)

Condition: Cancer Survivor
Interventions: Drug: carvedilol; Other: placebo; Other: pharmacogenomic studies; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: questionnaire administration
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Acupressure in Controlling Nausea in Young Patients With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Condition: Recurrent Glioblastoma
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

Conditions: Melanoma; Metastatic Kidney Cancer
Intervention: Drug: Interleukin-2 (IL-2)
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified October 2011
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Biological: IMC-CS4
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified October 2011
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Robotic-Assisted Surgery in Treating Patients With Spine Tumors

Conditions: Adult Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Metastases
Intervention: Procedure: therapeutic conventional surgery
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Conditions: Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy; Other: laboratory biomarker analysis; Radiation: image-guided radiation therapy; Drug: carboplatin; Drug: paclitaxel; Radiation: stereotactic body radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Conditions: Breast Cancer; Metastatic Breast Cancer
Interventions: Procedure: 124 PET/CT imaging; Drug: Na134I; Drug: Tri-iodothyronine; Drug: Tri-iodothyronine
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2011
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Conditions: Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: Tamibarotene; Drug: Placebo
Sponsors: CytRx; CytRx
Recruiting - verified March 2012
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Conditions: Pain; Advanced Cancer
Intervention: Drug: Sativex®
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Conditions: Neurofibromatosis Type 2; Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
Sponsors: House Research Institute; House Research Institute; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Condition: Glioblastoma
Interventions: Drug: BKM120; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals; M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; University of California, San Francisco; University of California, Los Angeles
Recruiting - verified February 2012
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Conditions: Bone Cancer; Chondrosarcoma; Ewing's Sarcoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Drug: Feraheme; Procedure: MR Scan
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
Study of Cabazitaxel Plus Bavituximab as Second-line Chemotherapy for Patients With Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Prostatic Neoplasms
Intervention: Drug: Cabazitaxel plus bavituximab
Sponsors: University of California, Irvine; University of California, Irvine; Peregrine Pharmaceuticals
Recruiting - verified August 2011
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Conditions: Solid Tumors; Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Panobinostat, Cisplatin, Pemetrexed
Sponsors: University of California, Davis; University of California, Davis; Novartis Pharmaceuticals
Recruiting - verified April 2012
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin

Condition: Breast Cancer
Interventions: Drug: Gemcitabine and Carboplatin; Drug: P276-00 along with Gemcitabine and carboplatin
Sponsors: Piramal Healthcare Limited; Piramal Healthcare Limited
Recruiting - verified January 2012
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified January 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Condition: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062); Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Conditions: Multiple Myeloma; Renal Insufficiency
Interventions: Drug: BHQ880; Drug: BHQ990
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: capecitabine; Drug: GDC-0980; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: RO5083945; Drug: FOLFIRI; Drug: cetuximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Unrelated Donor Stem Cell Transplantation

Conditions: Severe Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Syndromes; Chronic Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
Sponsors: Scripps Health; Scripps Health
Recruiting - verified June 2011
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Conditions: Chondrosarcoma; Metastatic Chondrosarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified November 2011
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
Sponsors: Abbott; Abbott; Genentech
Recruiting - verified March 2012
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: pTVG-HP; Biological: rhGM-CSF
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: Eribulin mesylate 1.4 mg/m2 intravenous; Drug: Dacarbazine of 850 mg/m2, or 1,000 mg/m2, or 1,200 mg/m2 IV
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood; Hodgkin's Disease; Non-Hodgkin's Lymphoma
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Panobinostat
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Novartis
Recruiting - verified November 2011
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Conditions: Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
Interventions: Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Biological: bevacizumab; Procedure: therapeutic conventional surgery; Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A; Other: laboratory biomarker analysis; Other: pharmacological study; Drug: irinotecan hydrochloride
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Biological: IMC-3G3
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

Conditions: Hematologic Malignancies; Nonmalignant Diseases; Immunodeficiencies; Hemoglobinopathies; Genetic Inborn Errors of Metabolism; Fanconi's Anemia,; Thalassemia; Sickle Cell Disease
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Thrasher Research Fund
Recruiting - verified September 2011
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation

Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Procedure: positron emission tomography/computed tomography (PET/CT); Radiation: fludeoxyglucose F 18
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants

Condition: Breast Cancer
Intervention: Procedure: SPY Intra-Operative Angiography
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
Effectiveness of Open and Robotic Prostatectomy

Condition: Prostate Cancer
Intervention: Other: Questionnaire
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; The Cleveland Clinic; Johns Hopkins University; University of California, San Francisco; University of Michigan; Vanderbilt University; Washington University School of Medicine
Recruiting - verified May 2012
Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study

Conditions: Colorectal Neoplasms; Colonic Polyps; Colorectal Cancer
Intervention: Device: Technically Improved High Definition NBI Colonoscopy System
Sponsors: VA Palo Alto Health Care System; VA Palo Alto Health Care System; Kansas City Veteran Affairs Medical Center
Recruiting - verified January 2012
A Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index

Conditions: Precancerous Condition; Colorectal Adenomas; BMI Greater Than or Equal to 30, With Decimals Rounded to the Nearest Whole Integer
Intervention: Drug: Metformin
Sponsors: University of California, Irvine; University of California, Irvine; National Cancer Institute (NCI)
Recruiting - verified March 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Condition: Prostate Cancer
Intervention: Drug: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2012
Minimally Invasive Surgery in Treating Patients With Spinal Tumors

Conditions: Adult Spinal Cord Neoplasm; Childhood Spinal Cord Neoplasm; Recurrent Adult Spinal Cord Neoplasm; Recurrent Childhood Spinal Cord Neoplasm; Spinal Bone Metastases; Spinal Cord Metastases
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic conventional surgery; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
Sponsors: University of California, San Francisco; University of California, San Francisco; Thrasher Research Fund
Recruiting - verified September 2011
Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

Condition: Metastatic Lung Cancer
Intervention: Device: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)

Condition: Stage IV Non-small Cell Lung Cancer
Intervention: Drug: Belionstat, Carboplatin, Paclitaxel
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; TopoTarget A/S
Recruiting - verified May 2012
ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: PF-05082566; Drug: rituximab; Drug: PF-05082566
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Fear of Recurrence Pilot Intervention for Women With Breast Cancer

Condition: Cancer Recurrence
Intervention: Behavioral: Acceptance and Commitment Therapy
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Drug: MM-302
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified November 2011
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors

Condition: Breast Neoplasms
Interventions: Drug: Metformin; Drug: Placebo; Behavioral: Lifestyle intervention; Behavioral: Standard printed dietary guidelines
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified February 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: PRI-724
Sponsors: Prism Pharma Co., Ltd.; Prism Pharma Co., Ltd.; PharmaNet/i3
Recruiting - verified May 2012
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Conditions: Metastatic Cancer; Cancer; Solid Tumors
Intervention: Drug: BIND-014
Sponsors: BIND Biosciences; BIND Biosciences
Recruiting - verified June 2011
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Solid Tumors

Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: GDC-0980; Drug: paclitaxel
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Condition: Lung Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2011
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 1 mg/kg; Drug: MK-3475 3 mg/kg; Drug: MK-3475 10 mg/kg; Drug: MK-3475 MEL; Drug: MK-3475 NSCLC
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)

Condition: Advanced Cancer
Interventions: Drug: ridaforolimus; Drug: MK-0752; Drug: MK-2206
Sponsors: Merck; Merck
Recruiting - verified May 2012
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified April 2012
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)

Condition: Invasive Lobular and Ductal Carcinoma
Interventions: Radiation: Hypofractionated Whole Breast Radiation Therapy; Radiation: Intraoperative Electron Radiation Therapy
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
NP2 Enkephalin For Treatment of Intractable Cancer Pain

Conditions: Intractable Pain; Neoplasms
Interventions: Biological: NP2; Biological: Placebo
Sponsors: Diamyd Inc; Diamyd Inc; Paragon Biomedical; invivodata, Inc.
Recruiting - verified January 2012
Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Genetic: western blotting; Genetic: nucleic acid sequencing; Procedure: therapeutic conventional surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study

Conditions: Colorectal Neoplasm; Colonic Polyps
Intervention: Device: Close focus HD NBI Colonoscopy System
Sponsors: VA Palo Alto Health Care System; VA Palo Alto Health Care System; Kansas City Veteran Affairs Medical Center
Recruiting - verified January 2012
A Study of LY2875358 in Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: LY2875358; Drug: LY2875358 + erlotinib; Drug: LY2875358 at MTD
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Condition: Neoplasms
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32

Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Condition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm); Drug: Fluorouracil/cisplatin (control arm)
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.
Recruiting - verified April 2012
BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Phase 1 Study of LY2787106 in Cancer and Anemia

Condition: Anemia
Intervention: Drug: LY2787106
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Intervention: Drug: BMS-906024
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations

Condition: Lymphangioma
Intervention: Drug: Sildenafil
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Condition: Oral Mucositis
Interventions: Device: MuGard; Device: Control Rinse
Sponsors: Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc.
Recruiting - verified April 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors

Conditions: Recurrent Renal Cell Cancer; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer
Interventions: Procedure: fluorescence imaging; Procedure: laparoscopic surgery; Drug: indocyanine green
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012
ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Condition: Hepatocellular Carcinoma
Interventions: Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol); Drug: Placebo
Sponsors: Polaris Group; Polaris Group
Recruiting - verified March 2012
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer

Conditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified February 2012
Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

Conditions: Indolent Non-Hodgkin Lymphoma; Follicular Lymphoma; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Marginal Zone Lymphoma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging

Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton
Recruiting - verified December 2011
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer

Conditions: Breast Neoplasms; HER2 Protein, Human; Geriatric Health Services
Interventions: Drug: Lapatinib; Drug: Trastuzumab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; GlaxoSmithKline; Genentech
Recruiting - verified January 2012
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: Hsp90 inhibitor STA-9090; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Genetic: RNA analysis; Other: spectrophotometry; Genetic: reverse transcriptase-polymerase chain reaction; Genetic: gene expression analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Condition: Solid Organ Tumors
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Condition: CNS Germ Cell Tumor
Intervention: Drug: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified February 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified February 2012
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: capecitabine; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified October 2011
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Dose Escalation Study to Determine Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301

Condition: Cancer
Intervention: Drug: TKM-080301
Sponsors: Tekmira Pharmaceuticals Corporation; Tekmira Pharmaceuticals Corporation
Recruiting - verified January 2012
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: RO5185426; Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Trial of Microdosing Carboplatin

Conditions: Carcinoma, Non-Small-Cell Lung; Urinary Bladder Neoplasms
Intervention: Drug: Carbon-14-labeled carboplatin
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified December 2011
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging

Condition: Breast Cancer
Intervention: Device: Diffuse Optical Spectroscopy Imaging
Sponsors: University of California, Irvine; Montana Compton; American College of Radiology Imaging Network; Massachusetts General Hospital; University of Pennsylvania; Dartmouth-Hitchcock Medical Center; Brown University; University of San Francisco
Recruiting - verified October 2011
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Aldesleukin With or Without Aflibercept in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Intervention: Drug: Amrubicin
Sponsors: University of Utah; University of Utah
Recruiting - verified January 2012
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Conditions: Neuroendocrine Tumors; Carcinoid Tumors
Intervention: Drug: Pasireotide Long Acting Release (LAR)
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of AMG 337 in Subjects With Advanced Solid Tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 337
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor

Condition: Advanced Solid Tumors
Interventions: Drug: MEDI3617; Drug: MEDI3617 - Dose Expansion (CRC); Drug: MEDI3617 - Dose Expansion (NSCLC); Drug: MEDI3617 Single-Agent Optional Dose Expansion; Drug: MEDI3617 + Bev Q3W Dose Escalation; Drug: MEDI3617 + Bev Q2W Dose Escalation; Drug: MEDI3617 + Bev Optional Dose Expansion; Drug: MEDI3617 + Weekly Pax Dose Escalation; Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc; Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: everolimus
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus; Drug: cyclophosphamide; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
GDC-0449 in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: vismodegib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

Conditions: Stomach Cancer; Esophageal Cancer
Interventions: Biological: Ramucirumab; Drug: Placebo; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Combination With Gemcitabine in Advanced Pancreatic Cancer

Condition: Pancreatic Neoplasms
Intervention: Drug: BAY86-9766+Gemcitabine
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Conditions: Advanced Solid Tumors; Tumors; Cancer
Interventions: Drug: MK-2206; Drug: Paclitaxel; Drug: Trastuzumab
Sponsors: University of California, San Francisco; University of California, San Francisco; Merck
Recruiting - verified March 2012
Entinostat and Anastrozole or Tamoxifen in Treating Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Lymphoepithelioma of the Oropharynx; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions: Procedure: transoral robotic surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified March 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Conditions: Adenocarcinoma of the Esophagus; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Stage IV Esophageal Cancer; Stage IV Gastric Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: everolimus; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
A Study in Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Cixutumumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012
Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

Conditions: Paravertebral Catheter Insertion; Mastectomy; Breast Cancer
Interventions: Procedure: Placebo (normal saline) Continuous Infusion; Procedure: Ropivicaine 0.4% Continuous Infusion
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified March 2012
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244; Drug: Erlotinib; Drug: AZD6244 + Erlotinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
A Study of LY2157299 in Patients With Hepatocellular Carcinoma

Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Institutional Registry for Prostate Cancer Radiosurgery

Conditions: Prostate Cancer Treated by Radiosurgery Early Risk; Prostate Cancer Treated by Radiosurgery Intermediate Risk
Intervention:
Sponsors: Florida Robotic Radiosurgery Association; Florida Robotic Radiosurgery Association
Recruiting - verified April 2012
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Condition: Solid Tumor
Intervention: Drug: ARQ 736
Sponsors: ArQule; ArQule
Recruiting - verified October 2011
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Conditions: Lymphoma, Non-Hodgkin; Lymphoma, B-cell; Lymphoma, B-cell, Diffuse
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified April 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Condition: Chronic Myelogenous Leukemia in Chronic Phase
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

Conditions: Ewing's Sarcoma; Primitive Neuroectodermal Tumor (PNET); Askin's Tumor of the Chest Wall; Extraosseous Ewing's Sarcoma (EOE)
Intervention: Drug: Zalypsis
Sponsors: PharmaMar; PharmaMar
Recruiting - verified August 2011
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Conditions: BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Dietary Supplement: soy isoflavones; Other: placebo; Other: questionnaire administration; Procedure: magnetic resonance imaging; Procedure: biopsy; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: mammography
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); California Breast Cancer Research Program
Recruiting - verified May 2012
Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery

Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Other: laser spectroscopy; Procedure: breast imaging study; Procedure: magnetic resonance imaging; Procedure: mammography; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma
Intervention: Drug: PD 0332991
Sponsors: University of California, San Francisco; University of California, San Francisco; Pfizer
Recruiting - verified January 2012
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Conditions: Non Small Cell Lung Cancer; NSCLC
Interventions: Drug: OSI-906; Drug: Erlotinib; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012
Evaluation of the Cook Biodesign Plastic Surgery Matrix

Conditions: Breast Cancer; Breast Reconstruction; Nipple Reconstruction
Intervention: Device: Nipple reconstruction
Sponsors: Cook; Cook
Recruiting - verified March 2012
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Condition: Glioma
Interventions: Drug: LY2157299; Drug: Radiation; Drug: Temozolomide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: Drug: U3-1287; Drug: Erlotinib
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

Conditions: Healthy, no Evidence of Disease; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2
Interventions: Other: questionnaire administration; Other: survey administration; Other: counseling intervention; Other: educational intervention
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Conditions: Pigmented Villonodular Synovitis; Diffuse-type Giant Cell Tumor; Tenosynovial Giant Cell Tumor
Intervention: Drug: nilotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis
Recruiting - verified June 2011
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Study of PX-866 and Docetaxel in Solid Tumors

Conditions: Non Small Cell Lung Cancer (NSCLC); Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Docetaxel; Drug: PX-866 and Docetaxel
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified March 2012
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: isotretinoin; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Conditions: Advanced Nonhematologic Malignancies; Carcinoma, Basal Cell
Intervention: Drug: TAK-441
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Axitinib (AG-013736); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Dendritic Cell Vaccine for Patients With Brain Tumors

Conditions: Glioma; Anaplastic Astrocytoma; Anaplastic Astro-oligodendroglioma; Glioblastoma
Intervention: Biological: autologous tumor lysate-pulsed DC vaccination
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified September 2010
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Predictors of Ovarian Insufficiency in Young Breast Cancer Patients

Conditions: Breast Cancer; Ovarian Insufficiency; Ovarian Failure
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; University of Pennsylvania; American Cancer Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Conditions: Hematopoietic/Lymphoid Cancer; Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Cytomegalovirus Infection; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: infection prophylaxis and management; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: DNA analysis; Genetic: RNA analysis; Procedure: management of therapy complications; Drug: ganciclovir; Drug: valganciclovir; Drug: foscarnet sodium; Procedure: antiviral therapy; Genetic: polymerase chain reaction; Genetic: protein expression analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Low Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction

Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Lymphomas; Bone Marrow Failure; Hemoglobinopathy; Immune Deficiency; Osteopetrosis; Cytopenias; White Blood Cell Abnormalities; Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
Sponsors: University of California, San Francisco; University of California, San Francisco
Available - verified June 2011
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsors: Oxford BioMedica; Oxford BioMedica; MedSource
Recruiting - verified February 2012
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)

Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib (GDC-0449); Drug: vismodegib (GDC-0449); Drug: vismodegib (GDC-0449)
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Condition: Cancer
Interventions: Drug: Trametinib (GSK1120212); Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel; Drug: Cisplatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Conditions: Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer
Interventions: Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunoenzyme technique; Biological: modified vaccinia virus ankara vaccine expressing p53
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Conditions: Lung Cancer; Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer Small Cell Lung Cancer (SCLC); Mesothelioma
Interventions: Procedure: Stereotactic Body Radiation Therapy (SBRT); Drug: Iohexol; Radiation: Computed Tomography (CT); Device: Cyberknife; Device: Trilogy; Device: True Beam
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: trabectedin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Sarcoma Alliance for Research through Collaboration
Recruiting - verified November 2011
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

Conditions: Juvenile Pilcytic Astrocytoma (JPA); Pleomorphic JPA; Diffuse Astrocytoma (Fibrillary, Gemistocytic, Giant Cell, or Pleomorphic Xanthoastrocytoma); Low Grade Oligoastrocytoma; Low Grade Oligodendroglioma; Low Grade Glioma NOS
Intervention: Drug: Poly ICLC
Sponsors: University of California, San Diego; University of California, San Diego; Emory University
Recruiting - verified June 2011
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

Conditions: Cancers; Chronic Pain
Intervention: Device: Implantation of Morphine Sulfate delivring programmable pump
Sponsors: The Alfred E. Mann Foundation for Scientific Research; The Alfred E. Mann Foundation for Scientific Research
Recruiting - verified March 2012
A Study of IMC-3G3 in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3; Drug: doxorubicin; Drug: dexrazoxane
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study

Condition: Colorectal Cancer
Intervention: Procedure: Early urinary catheter removal
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas

Conditions: Adult Anaplastic Astrocytoma; Recurrent Grade III Glioma; Recurrent Grade IV Glioma; Adult Anaplastic Oligodendroglioma; Adult Brain Tumor; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Recurrent Adult Brain Tumor; Adult Anaplastic Oligoastrocytoma; Recurrent High Grade Glioma
Interventions: Drug: flucytosine; Other: polymerase chain reaction; Other: immunohistochemistry staining method; Biological: gene therapy; Other: pharmacological study; Other: 3-Tesla magnetic resonance imaging; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery; Biological: E. coli CD-expressing genetically modified neural stem cells
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified April 2012
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Condition: Neuroblastoma
Interventions: Drug: busulfan; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Other: pharmacological study; Other: questionnaire administration; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: iobenguane I 131
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Condition: Solid Tumor
Intervention: Drug: PEGPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2011
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging

Condition: Lung Cancer
Interventions: Device: Real time position management system; Device: LS PET/CT; Drug: 18-FDG
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2011
A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma

Condition: Gastric Cancer
Interventions: Biological: Ramucirumab DP; Drug: Placebo; Drug: Paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract

Conditions: Upper Aerodigestive Tract Lesions; Neoplasms, Oropharyngeal; Oropharyngeal Cancer; Neoplasms, Hypopharyngeal; Hypopharyngeal Cancer; Head and Neck Neoplasms; UADT Neoplasms; Carcinoma, Squamous Cell; Papilloma
Interventions: Device: Direct Rigid Endoscopy; Device: Transnasal Flexible Endoscopy with Narrowband Imaging
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)

Condition: Melanoma
Interventions: Drug: Axitinib; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: University of California, San Francisco; Adil Daud
Recruiting - verified January 2012
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Condition: Advanced Solid Tumors
Intervention: Drug: ARQ 197 as monotherapy or in combination with other drug(s)
Sponsors: ArQule; ArQule
Recruiting - verified January 2012
Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Conditions: Anal Cancer; Neoplasm of Uncertain Malignant Potential; Nonneoplastic Condition; Precancerous Condition
Interventions: Other: clinical observation; Procedure: infrared photocoagulation therapy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma
Interventions: Drug: bortezomib; Drug: fludarabine phosphate; Other: melphalan; Radiation: intensity-modulated radiation therapy; Radiation: total marrow irradiation; Radiation: tomotherapy; Drug: tacrolimus; Drug: sirolimus
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

Conditions: Fatigue; Multiple Myeloma
Interventions: Drug: armodafinil; Drug: Placebo
Sponsors: Oncotherapeutics; Oncotherapeutics; Cephalon
Recruiting - verified February 2012
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers

Conditions: Head and Neck Cancer; Head and Neck Cancers
Interventions: Drug: Dichloroacetate; Device: EF5
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Acupuncture for Sleep Disruption in Cancer Survivors

Conditions: Sleep Initiation and Maintenance Disorders; Breast Cancer
Intervention: Procedure: acupuncture
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified January 2012
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis; Other: immunologic technique
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Conditions: Neoplasm; Cancer; Tumors
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Prostate Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Drug: doxorubicin-GnRH agonist conjugate AEZS-108
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; AEterna Zentaris
Recruiting - verified May 2012
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma

Conditions: Glioblastoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Interventions: Biological: Toca 511; Drug: 5-FC
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified November 2011
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified November 2011
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Intraoperative Radiotherapy for Early Stage Breast Cancer

Condition: Breast Cancer
Intervention: Device: Intraoperative Radiotherapy
Sponsors: Hoag Memorial Hospital Presbyterian; Hoag Memorial Hospital Presbyterian
Recruiting - verified April 2012
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Conditions: Lymphoma; Non-Hodgkin's Lymphoma; Hodgkin Disease; Multiple Myeloma; Leukemia; Lymphocytic; Chronic
Intervention: Drug: PCI-24781
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified March 2012
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Condition: Advanced and Selected Solid Tumors
Intervention: Drug: BKM120 + GSK1120212
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Conditions: Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder
Interventions: Procedure: Stereotactic Body Radiotherapy; Drug: Gemcitabine100 mg/m2; Drug: Cisplatin; Drug: Carboplatin; Drug: Capecitabine; Drug: 5FU
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Conditions: Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: DNA methylation analysis
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Genentech
Recruiting - verified February 2012
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Condition: Solid Cancers
Interventions: Drug: bevacizumab; Drug: MINT1526A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Condition: Prostate Cancer
Intervention: Other: MRI examination
Sponsors: Radboud University; Radboud University; Siemens AG; Mount Vernon Hospital; Multi-Imagem and CDPI, Rio de Janeiro, Brasil; Norwegian University of Science and Technology; University of California, Los Angeles; University Hospital, Ghent; Johns Hopkins University; German Cancer Research Center; Medical University of Vienna; University Health Network, Toronto; University of Heidelberg
Recruiting - verified July 2011
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Condition: Sarcoma
Interventions: Biological: Trivalent ganglioside vaccine; Biological: OPT-821
Sponsors: MabVax Therapeutics, Inc.; MabVax Therapeutics, Inc.
Recruiting - verified March 2012
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

Condition: Glioma
Intervention: Drug: nilotinib
Sponsors: University of California, San Diego; University of California, San Diego; Novartis
Recruiting - verified January 2012
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Condition: Neoplasm Malignant
Intervention: Drug: Cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Conditions: Cachexia; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria

Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton Beam Radiotherapy; Drug: Sorafenib
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified June 2011
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy

Condition: Non-small-cell Lung Cancer
Intervention: Drug: AUY922
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Conditions: Stage IIIC Melanoma; Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform; Procedure: HE4 assay on Architect i1000SR platform; Procedure: Transvaginal Ultrasound
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
Recruiting - verified February 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

Conditions: Glioblastoma; Cancer of Brain and Nervous System; Glioblastoma Multiforme
Interventions: Drug: Temozolomide; Procedure: Stereotactic Radiosurgery
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Conditions: Acute Myelogenous Leukemia; Diffuse Large B-Cell Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma
Interventions: Drug: BMS-936564 (Anti-CXCR4); Drug: BMS-936564 (Anti-CXCR4)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Tracking Renal Tumors After Cryoablation Evaluation

Condition: Kidney Neoplasms
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified October 2011
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients

Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease; Multiple Myeloma
Interventions: Drug: TXA127; Drug: Placebo
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified April 2012
Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Tumors of the Brain

Condition: Glioma
Intervention: Drug: 5-Aminolevuline Acid
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012
Dose Escalation Study of INK128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Conditions: Relapsed or Refractory Multiple Myeloma; Waldenstrom Macroglobulinemia
Intervention: Drug: INK128
Sponsors: Intellikine; Intellikine
Recruiting - verified January 2012
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Reducing Breast Cancer Recurrence With Weight Loss

Conditions: Breast Cancer; Overweight; Obesity
Interventions: Behavioral: Intensive Group; Behavioral: Less Intensive Group
Sponsors: University of California, San Diego; University of California, San Diego; Washington University School of Medicine; University of Colorado, Denver; University of Alabama at Birmingham
Recruiting - verified March 2010
FNA Tumor Sampling for CD137 Modulation: A Pilot Study

Conditions: Head and Neck Cancer; Breast Cancer; Head and Neck Cancers
Intervention: Procedure: FNA Biopsy
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: ADXS11-001 (Lm-LLO-E7); Drug: Placebo Control
Sponsors: Advaxis, Inc.; Advaxis, Inc.
Recruiting - verified January 2012
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Conditions: Skin Cancers; Carcinoma, Basal Cell; Skin Cancer; Basal Cell Carcinoma
Intervention: Drug: Itraconazole
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2011
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

Condition: Endometrial Cancer
Intervention: Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Recurrent or Refractory Medulloblastoma; Locally Advanced or Metastatic Basal Cell Carcinoma
Intervention: Drug: LEQ506
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Conditions: Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions: Drug: Pazopanib (GW786034); Drug: Paclitaxel
Sponsors: Stanford University; Sandy Srinivas; GlaxoSmithKline
Recruiting - verified April 2012
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

Condition: Solid Cancers
Intervention: Drug: GDC-0623
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified December 2011
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Condition: Colorectal Cancer
Intervention: Drug: Veliparib
Sponsors: Abbott; Abbott
Recruiting - verified January 2012
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Untreated Adult Acute Myeloid Leukemia; Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions: Biological: filgrastim; Drug: clofarabine; Drug: cytarabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

Conditions: Colorectal Neoplasms; Liver Neoplasms
Intervention: Device: Yttrium-90 Radioactive Resin Microspheres
Sponsors: University of California, San Diego; University of California, San Diego; Sirtex Medical
Recruiting - verified May 2011
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Conditions: Breast Cancer; Stage IV Breast Cancer
Interventions: Procedure: positron emission tomography; Radiation: copper Cu 64-DOTA-trastuzumab; Procedure: Biopsy; Other: Immunohistochemistry staining method; Other: laboratory biomarker analysis; Genetic: mutation analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified May 2012
MEK Inhibitor AZD6244 in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: AZD6244
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Conditions: Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Acute Myeloid Leukemia; Multiple Myeloma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified January 2012
Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer

Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Drug: ixabepilone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Contrast-Enhanced CT Scan and Contrast-Enhanced MRI in Diagnosing and Staging Liver Cancer in Patients With Chronic Liver Disease

Condition: Liver Cancer
Interventions: Drug: iodinated contrast dye; Drug: motexafin gadolinium; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Pineal Gland Astrocytoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy

Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified January 2012
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

Condition: Neuroma, Acoustic
Interventions: Procedure: Microsurgery; Procedure: Stereotactic radiation therapy
Sponsors: Stanford University; Stanford University; University of Cincinnati; Baylor College of Medicine; Weill Medical College of Cornell University; University of Iowa; University of Texas; George Washington University
Recruiting - verified March 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Condition: Breast Cancer
Interventions: Drug: Cisplatin; Drug: Rucaparib; Drug: Cisplatin
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Clovis Oncology, Inc.
Recruiting - verified March 2012
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Stanford Accelerated Recovery Trial (START)

Conditions: Pain; Breast Cancer; Lung Cancer
Interventions: Drug: Gabapentin; Drug: Placebo
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Drug: veliparib (ABT-888); Drug: carboplatin; Drug: gemcitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified March 2012
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Hypo-fractionated radiotherapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas

Conditions: Brain Cancer; Brain Stem Tumors; Pontine Tumors
Intervention: Biological: Rindopepimut
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified July 2011
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma

Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified April 2012
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

Condition: Breast Cancer
Interventions: Other: History and Physical Exam; Other: Grip Strength Measurement; Behavioral: Surveys; Other: Blood Collection; Procedure: Ultrasound of Hand/Wrist
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways

Condition: Lung Cancer
Interventions: Radiation: Stereotactic Body Radiation; Radiation: Radiofrequency Ablation
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012
Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Conditions: Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Drug: paclitaxel; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma

Conditions: Hemangiosarcoma; Soft Tissue Sarcoma
Intervention: Drug: Paclitaxel in combination with Bevacizumab
Sponsors: Stanford University; Stanford University; Genentech
Recruiting - verified February 2012
Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

Conditions: Locally Advanced Breast Cancer; Metastatic (Stage IV) Breast Cancer; Stage III-IV Breast Cancer or Inflammatory
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); Palo Alto Research Center
Recruiting - verified March 2012
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

Conditions: Stomach Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastric (Stomach) Cancer; Esophageal Cancer; Gastrointestinal Stromal Tumor (GIST)
Interventions: Procedure: Blood draw; Procedure: Tissue tumor biopsy
Sponsors: Stanford University; Stanford University; State of California; National Institutes of Health (NIH)
Recruiting - verified June 2010
Genomic Analysis of Pediatric Bone Tumors

Condition: Bone Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure

Conditions: Brain Cancer; Cancer
Intervention: Procedure: Bone marrow specimen banking
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
CyberKnife Radiosurgery for Localized Prostatic Carcinoma

Condition: Prostate Cancer
Interventions: Radiation: CyberKnife Radiosurgery; Radiation: CyberKnife Radiosurgery
Sponsors: CyberKnife Centers of San Diego; CyberKnife Centers of San Diego
Recruiting - verified September 2011
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Conditions: Liver Neoplasms; Adenoma; Carcinoma; Liver Abscess
Intervention: Drug: Gadoxetic Acid Disodium (Primovist/Eovist, BAY86-4873)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health
Recruiting - verified December 2011
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
Magnetic Resonance Imaging of Breast Cancer

Conditions: Breast Cancer; Breast Cancer Non-invasive Breast Cancer
Intervention: Procedure: MRI
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified May 2012
Ketoconazole and Dexamethasone in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ketoconazole, hydrocortisone; Drug: Ketoconazole, dexamethasone
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Conditions: Acute Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Biphenotypic Leukemia; Pre-leukemic Syndromes; Monosomy 7; Bone Marrow Clonal Malformations; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia
Intervention: Other: Withdrawal of immunosuppression and donor lymphocyte infusion
Sponsors: University of California, San Francisco; University of California, San Francisco; All Children's Hospital
Recruiting - verified March 2012
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

Condition: Lung Cancer
Interventions: Device: Real-time Position Management system; Device: Discovery ST multislice PET/CT scanner; Device: Infinia Hawkeye SPECT/CT gamma camera; Device: Pinnacle3 treatment planning system; Device: SKYLight nuclear camera; Drug: DTPA; Drug: TECHNETIUM TC 99M MAA
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2011
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

Conditions: Gastrointestinal Neoplasms; Gynecologic Cancers; Gynecologic Cancers Cervical Cancer; Gastric (Stomach) Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastrointenstinal Stromal Tumor (GIST); Colon/Rectal Cancer; Colon/Rectal Cancer Colon Cancer; Colon/Rectal Cancer Rectal Cancer; Colon/Rectal Cancer Anal Cancer; Anal Cancer; Hepatobiliary Cancers; Hepatobiliary Cancers Liver; Pancreatic Cancer
Interventions: Procedure: Blood Draw; Procedure: Frozen Tumor Specimens
Sponsors: Stanford University; Stanford University; Caring for Carcinoid Foundation; GI Cancer Research Gift Fund
Not yet recruiting - verified May 2010
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: Aurora A kinase inhibitor MLN8237; Drug: bortezomib
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified March 2012
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib; Drug: etoposide
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)

Condition: Locally Advanced or Metastatic Solid Tumors
Intervention: Drug: MK2206 plus AZD6244
Sponsors: Merck; Merck; AstraZeneca
Recruiting - verified May 2012
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified April 2012
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified January 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

Conditions: Endometrial Cancer; Endometrial Neoplasms
Intervention: Drug: XL147 (SAR245408)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Electronic Brachytherapy for the Treatment of NMSC

Conditions: Basal Cell Carcinoma; Squamous Cell Carcinoma
Intervention: Radiation: electronic brachytherapy
Sponsors: Xoft, Inc.; Xoft, Inc.
Recruiting - verified March 2012
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Drug: VPA FEC100
Sponsors: University of California, San Francisco; University of California, San Francisco; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: cixutumumab; Drug: sorafenib tosylate; Other: laboratory biomarker analysis
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stage IV Surgery Versus Best Medical Therapy

Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2012
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Condition: Breast Cancer
Intervention: Other: ChemoFX Assay
Sponsors: Precision Therapeutics; Precision Therapeutics; Department of Defense
Recruiting - verified December 2011
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety Study of PLX108-01 in Patients With Solid Tumors

Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
The Biorepository for Scripps Health

Condition: Cancer
Intervention: Other: No study intervention
Sponsors: Scripps Translational Science Institute; Scripps Translational Science Institute
Recruiting - verified January 2012
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Conditions: Advanced Solid Tumors With FGFR1 Amplication,; Advanced Solid Tumors With FGFR2 Amplication,; Advanced Solid Tumors With FGFR3 Mutation
Intervention: Drug: BGJ398
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Intervention: Drug: sorafenib with temsirolimus
Sponsors: University of California, San Francisco; University of California, San Francisco; Northwestern University
Recruiting - verified March 2012
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Conditions: Alopecia; Breast Cancer
Interventions: Drug: bimatoprost ophthalmic solution; Drug: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: bortezomib + Temozolomide; Radiation: external beam radiation therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

Condition: Hepatocellular Cancer
Intervention: Drug: Sorafenib - dose escalation
Sponsors: Columbia University; Columbia University; Bayer; Onyx Pharmaceuticals
Recruiting - verified October 2011
Letrozole as a Treatment of Endometrial Cancer

Condition: Endometrial Carcinoma
Intervention: Drug: Letrozole
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified August 2011
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

Conditions: Central Nervous System Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Condition: Refractory Solid Tumors in Children
Intervention: Drug: combination of Irinotecan, vincristine, temozolomide and bevacizumab
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified October 2009
IMGN901 in Combination With Lenalidomide and Dexamethasone

Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified October 2011
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

Condition: Lung Cancer
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Condition: B-cell Malignancies
Intervention: Drug: MEDI-551
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Condition: Bone Metastases
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)

Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate; Drug: cilengitide; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: magnetic resonance imaging
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of Prostate Samples in Predicting Cancer Recurrence in Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Hydroxychloroquine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Stanford University; Yale University; University of Maryland; Genentech
Recruiting - verified April 2012
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Condition: Ovarian Neoplasms
Interventions: Drug: Vorinostat; Drug: Vorinostat
Sponsors: Gynecologic Oncology Associates; Gynecologic Oncology Associates; Merck
Recruiting - verified June 2011
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

Condition: Hepatocellular Carcinoma
Interventions: Drug: GC33; Drug: Sorafenib
Sponsors: Chugai Pharmaceutical; Chugai Pharmaceutical; Hoffmann-La Roche
Recruiting - verified April 2012
Dose-Escalation Study of GSK2126458

Conditions: Advanced Solid Tumor; Solid Tumours
Intervention: Drug: GSK2126458
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified September 2011
A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia; Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Methotrexate; Drug: Filgrastim
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; GlaxoSmithKline
Recruiting - verified November 2011
Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer

Condition: Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified June 2011
Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Condition: Prostate Cancer
Intervention: Radiation: Stereotactic Radiosurgery using the Novalis Tx
Sponsors: San Diego Radiosurgery; San Diego Radiosurgery
Recruiting - verified August 2011
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Of PF-04449913 In Select Hematologic Malignancies

Condition: Hematologic Malignancies
Intervention: Drug: PF-04449913
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Treatment of Blood Clots in Children With Cancer

Condition: Venous Thromboembolism
Intervention: Drug: Fragmin
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Imaging and Biomarkers of Hypoxia in Solid Tumors

Condition: Neoplasms
Interventions: Procedure: PET Scan; Drug: EF5; Drug: Carbogen
Sponsors: Stanford University; Stanford University
Recruiting - verified March 2012
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans

Condition: Colorectal Neoplasms
Interventions: Behavioral: LHWO about CRC; Behavioral: Nutrition Education + CRC brochure
Sponsors: University of California, San Francisco; University of California, San Francisco; San Francisco State University; NICOS Chinese Health Coalition
Recruiting - verified April 2012
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Conditions: Brain Cancer; Neoplasm Metastasis; Lung Cancer; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Vorinostat; Procedure: Radiation Therapy
Sponsors: Stanford University; Griffith R Harsh; National Comprehensive Cancer Network
Recruiting - verified February 2012
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
GDC-0449 in Treating Adult Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Hedgehog antagonist GDC-0449
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Conditions: Pituitary Adenomas; Prolactinomas; Cushing's Disease
Intervention: Drug: Lapatinib
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified November 2011
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Short-Term Fasting: Impact on Toxicity

Condition: Fasting in Malignant Solid Tumors
Interventions: Other: Short-term fasting; Other: Modified fast
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6

Condition: Colon Cancer With Metastases to the Liver
Interventions: Device: LC bead loaded with Irinotecan; Drug: FOLFOX6 and Avastin
Sponsors: University of Louisville; University of Louisville; Biocompatibles UK Ltd
Recruiting - verified November 2011
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Condition: Solid Cancers
Interventions: Drug: carboplatin; Drug: docetaxel; Drug: trastuzumab
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

Conditions: Brain Cancer; Neoplasm Metastasis; Cancer of Brain and Nervous System; Metastatic Malignant Neoplasm to Brain
Interventions: Procedure: Fractionated Stereotactic Radiosurgery; Device: Linear accelerator
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Condition: Cancer
Intervention: Drug: PF-04691502
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Condition: Solid Cancer
Intervention: Drug: cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Conditions: Leukemia-relapsed or Refractory; Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors

Conditions: Cancer Survivor; Cervical Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012
Ultrasound Hyperthermia Therapy After Implant Radiation Therapy in Treating Patients With Urinary Tract Cancer, Gynecologic Cancer, or Head and Neck Cancer

Condition: Cancer
Interventions: Procedure: ultrasound hyperthermia treatment; Radiation: brachytherapy
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified May 2009
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Lymphoseek
Sponsors: Navidea Biopharmaceuticals; Navidea Biopharmaceuticals
Recruiting - verified March 2012
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2011
Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701)

Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Hematopoietic Stem Cell Transplant
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified January 2012
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12 (cixutumumab); Biological: IMC-A12 (cixutumumab); Drug: sorafenib
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified October 2011
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Condition: Colon Cancer
Intervention:
Sponsors: Agendia; Agendia
Recruiting - verified March 2012
Study of Radiation Exposure and Bilateral Breast Cancer

Condition: Breast Cancer
Intervention: Other: questionaire, blood or saliva sample
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Translational Genomics Research Institute, Phoenix, Arizona.; University of Southern California; University of Virginia; Lund University; Ontario Cancer Registry; Northern California Cancer Center; Fred Hutchinson Cancer Research Center; University of Iowa; Danish Cancer Society; Beckman Research Institute; City of Hope National Medical Center; M.D. Anderson Cancer Center; Vanderbilt University School of Medicine; New York University School of Medicine; University of Chicago; University of California, Irvine; Stanford University
Recruiting - verified January 2012
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

Condition: Cancer
Intervention:
Sponsors: DiaTech Oncology; DiaTech Oncology
Recruiting - verified March 2011
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

Conditions: Brain Tumors; Central Nervous System Tumors
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

Conditions: Head and Neck Cancer; Cancer of Nasopharynx
Interventions: Drug: docetaxel; Drug: cisplatin; Drug: 5-Fluorouracil; Procedure: Chemoradiation; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Stanford University; A. Dimitrios Colevas
Recruiting - verified October 2011
Intellectual Impairment in Women With Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Cognitive Rehabilitation; Behavioral: Neurofeedback Training (randomized)
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3; Biological: ramucirumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); ImClone LLC
Recruiting - verified April 2012
Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Condition: Prostate Cancer
Intervention: Drug: Ketoconazole
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified November 2011
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: cone biopsy; Procedure: endocervical curettage; Procedure: histopathologic examination; Procedure: loop electrosurgical excision procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: high performance liquid chromatography; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Microwave Ablation of Resectable Liver Tumors

Conditions: Hepatocellular Carcinoma; Liver Cancer
Intervention: Device: Microwave Ablation
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Conditions: Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neutropenia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: recombinant human mannose-binding lectin
Sponsors: National Cancer Institute (NCI); Enzon Pharmaceuticals, Inc.; National Cancer Institute (NCI)
Recruiting - verified August 2007
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Conditions: Brain Cancer; Pediatric Cancers
Interventions: Drug: Bevacizumab; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified March 2012
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified June 2010
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Conditions: Liver Tumors; Hepatocellular Carcinoma; Hepatoma; Neoplasms
Intervention: Device: TheraSphere®
Sponsors: St. Joseph Hospital of Orange; St. Joseph Hospital of Orange
Recruiting - verified March 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: ursodiol; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: positron emission tomography (PET)
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Radiation: Conformal radiation
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Concentration and Activity of Lapatinib in Vestibular Schwannomas

Conditions: Vestibular Schwannoma; NF2; Neurofibromatosis 2; Acoustic Neuroma; Auditory Tumor
Intervention: Drug: lapatinib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; The Children's Tumor Foundation; GlaxoSmithKline; New York University; Ohio State University; House Ear Institute
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: NKTR-102; Drug: irinotecan
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
CyberKnife Radiosurgery for Locally Recurrent Prostate CA

Condition: Recurrent Prostate Cancer
Intervention: Radiation: CyberKnife Radiosurgery
Sponsors: CyberKnife Centers of San Diego; CyberKnife Centers of San Diego
Recruiting - verified September 2011
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Procedure: Transarterial Chemoembolization; Radiation: Proton Beam Radiotherapy
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified June 2011
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Interventions: Drug: RAD001; Drug: erlotinib
Sponsors: University of California, San Francisco; University of California, San Francisco; Genentech; Novartis Pharmaceuticals; The V Foundation for Cancer Research
Recruiting - verified March 2012
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Radiation: CyberKnife Stereotactic Radiotherapy; Procedure: Surgery
Sponsors: Accuray Incorporated; Accuray Incorporated; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study for Patients With Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: Proton Radiation; Radiation: Proton
Sponsors: Loma Linda University; Loma Linda University
Recruiting - verified May 2012
Open Label Extension In Cancer Patients

Conditions: Neoplasms; Bone Metastases
Intervention: Biological: Anti-NGF AB
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Conditions: Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); National Comprehensive Cancer Network
Recruiting - verified December 2011
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer.

Conditions: Metastatic Breast Cancer; Metastases, Brain
Interventions: Drug: capecitabine; Drug: lapatinib; Drug: trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma

Conditions: Low-grade Glioma; Astrocytoma; Oligodendroglioma; Mixed Oligoastrocytoma
Intervention: Drug: RAD001
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Condition: Carcinoma, Non-small Cell
Intervention: Drug: Dacomitinib (PF-00299804)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: lymphokine-activated killer cells; Drug: polifeprosan 20 with carmustine implant
Sponsors: National Cancer Institute (NCI); Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian
Recruiting - verified June 2009
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Conditions: Cancer; Oncology; Tumors; Advanced Malignancy; Advanced Solid Tumors; Oncology Patients
Intervention: Drug: AMG 208
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Intervention: Drug: gemcitabine plus carboplatin plus BSI-201
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Breast Cancer Research Foundation
Recruiting - verified December 2011
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified March 2012
Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Drug: exemestane; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Efficacy and Safety of Masitinib (AB1010) in Comparison to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap

Conditions: Smouldering Systemic Mastocytosis; Indolent Systemic Mastocytosis; Cutaneous Mastocytosis With Handicap; Mastocytosis
Interventions: Drug: masitinib (AB1010); Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified January 2012
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Autoantibody Blood Test in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunoenzyme technique; Other: immunohistochemistry staining method
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
American Breast Laser Ablation Therapy Evaluation

Condition: Benign Breast Conditions; Breast Fibroadenomas
Intervention:
Sponsors: Novian Health Inc.; Novian Health Inc.
Recruiting - verified November 2011
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver

Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab; Drug: 5-FU; Drug: oxaliplatin; Drug: leucovorin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Bristol-Myers Squibb
Recruiting - verified March 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines

Condition: Cervical Cancer
Interventions: Drug: parenteral chemotherapy; Other: imaging biomarker analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Radiation: copper Cu 64-ATSM; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: American College of Radiology Imaging Network; American College of Radiology Imaging Network
Recruiting - verified March 2012
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)

Conditions: Translocation, Genetic; Sarcoma, Soft Tissue
Interventions: Drug: Trabectedin; Drug: Doxorubicin
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified May 2012
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Conditions: Mucosal Melanoma; Acral Melanoma; Melanoma
Intervention: Drug: Nilotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Novartis
Recruiting - verified October 2011
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Conditions: Stomach Cancer; Gastric (Stomach) Cancer; Neoplasm of Cardioesophageal Junction; Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: capecitabine
Sponsors: Stanford University; Pamela L. Kunz; Genentech
Recruiting - verified February 2012
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Condition: Leukemia
Intervention: Drug: Midostaurin
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide); Drug: placebo
Sponsors: Ipsen; Ipsen
Recruiting - verified April 2012
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Permission to Collect Blood Over Time for Research

Conditions: Pancreatic Cancer; Gastrointestinal Neoplasms; Colon Rectal Cancer Adenocarcinoma; Esophageal Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatobiliary Neoplasm; Liver Carcinoma; Gallbladder Carcinoma; Bile Duct Carcinoma; Carcinoma of the Large Intestine; Anal Cancer
Intervention: Procedure: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas

Condition: Malignant Glioma
Interventions: Drug: Armodafinil; Other: Placebo
Sponsors: Dana-Farber Cancer Institute; Eudocia Quant Lee, MD; Dartmouth-Hitchcock Medical Center; University of California, San Diego; Beth Israel Deaconess Medical Center; Cephalon
Recruiting - verified December 2011
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified June 2011
Erlotinib in Treating Patients With a History of Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: erlotinib hydrochloride; Drug: placebo administration
Sponsors: University of California, Irvine; University of California, Irvine; National Cancer Institute (NCI)
Recruiting - verified March 2012
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
CryoSpray Ablation (TM) GI Patient Registry

Conditions: Barrett's Esophagus With or Without Dysplasia; Squamous Dysplasia of the Esophagus; Esophageal Cancer (Any Stage)
Intervention:
Sponsors: CSA Medical, Inc.; CSA Medical, Inc.
Recruiting - verified January 2012
Airway Epithelium Gene Expression: AEGIS II

Condition: Lung Cancer
Intervention: Device: Biomarker (not used as an intervention)
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; University of Pennsylvania; Columbia University; Temple University; Indiana University; University of Alabama at Birmingham; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Wisconsin, Madison; Medical University of South Carolina; National Jewish Health; Overlake Hospital Bellevue WA; Pulmonary and Allergy Associates of New Jersey; Pulmonary Associates of Arizona; William Jennings Bryan Dorn VA Medical Center; Virginia Commonwealth University; Jamaica Hospital Medical Center; North Florida/South Georgia Veterans Health System; Steward St. Elizabeth; University of California, Davis; Yale University Medical Center; The Cleveland Clinic; Johns Hopkins University
Recruiting - verified May 2012
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Condition: Osteosarcoma
Interventions: Drug: Saracatinib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified March 2012
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

Condition: Lung Cancer
Interventions: Other: high performance liquid chromatography; Other: pharmacological study; Procedure: radionuclide imaging; Procedure: single photon emission computed tomography; Radiation: radiation therapy; Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)

Condition: Depression
Intervention: Behavioral: Lifestyle Counseling with Emotional Freedom Techniques (EFT)
Sponsors: Soul Medicine Institute; Soul Medicine Institute
Recruiting - verified June 2011
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas

Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma; Malignant Astrocytoma NOS
Intervention: Drug: Nanoliposomal CPT-11
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified May 2012
Multiple Ascending Dose (MDX1105-01)

Condition: Cancer, Multiple Indications
Interventions: Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012
Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy

Condition: Neoplasms
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified February 2012
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Conditions: Colorectal Cancer; Colorectal Carcinoma; Liver Metastases
Interventions: Drug: Systemic chemotherapy (FOLFOX); Device: SIR-Spheres yttrium-90 microspheres; Drug: Systemic chemotherapy (FOLFOX)
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2012
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Non-Hodgkins Lymphoma; Sarcoma; Neuroblastoma
Intervention: Other: FDA Food Safety Guidelines
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified March 2010
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract

Conditions: Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Head and Neck Cancers; Oropharynx; Hypopharynx; Larynx
Interventions: Device: da Vinci Surgical Robot Platform; Procedure: Transoral Robotic Surgery
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Conditions: Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: DI-Leu16-IL2 immunocytokine; Biological: rituximab; Other: flow cytometry; Other: immunohistochemistry staining method; Other: pharmacological study; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: reverse transcriptase-polymerase chain reaction
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Potential Research Study Participant Registry

Conditions: Acne; Actinic Keratosis; Dysplastic Nevi; Eczema; Psoriasis; Skin Cancer; Rosacea; Leg Ulcers; Foot Ulcers; Atopic Dermatitis
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011
Improving Cancer Pain Management Through Self-Care

Conditions: Cancer; Pain
Intervention: Behavioral: PRO-SELF PLUS Pain Management Program
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Recruiting - verified March 2012
Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
Sponsors: University of California, Davis; University of California, Davis; Jacobus Pharmaceutical
Available - verified February 2012
International Pediatric Adrenocortical Tumor Registry

Condition: Adrenocortical Tumor
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

Conditions: Adenovirus Infection; EBV Infection
Intervention: Biological: Most Closely Matched CTLs with Adenovirus
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Brigham and Women's Hospital; Massachusetts General Hospital; M.D. Anderson Cancer Center; National Marrow Donor Program; The EMMES Corporation; Duke University; Beth Israel Deaconess Medical Center; Children's Hospital Los Angeles; National Heart, Lung, and Blood Institute (NHLBI); Children's Hospital Boston; University of Miami; Hackensack University Medical Center; University of California, Los Angeles
Recruiting - verified April 2012
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Conditions: Cancer; Solid Tumor
Intervention: Drug: CALAA-01
Sponsors: Calando Pharmaceuticals; Calando Pharmaceuticals
Recruiting - verified February 2012
Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Conditions: Melanoma; Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Intervention: Procedure: Collection of tumor and blood samples
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Green Tea or Water in Treating Patients With Prostate Cancer Undergoing Surgery

Condition: Prostate Cancer
Interventions: Dietary Supplement: green tea; Dietary Supplement: placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
Herbal Therapy for Treatment of Recurrent Prostate Cancer

Condition: Prostate Cancer
Intervention: Dietary Supplement: Prostate Health Cocktail
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified November 2011
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

Condition: Liver Cancer
Intervention: Drug: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified April 2012
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Panitumumab Pediatric Study

Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Conditions: MDS; AML; Solid Tumors; Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Conditions: Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: floxuridine; Genetic: proteomic profiling; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: liquid chromatography; Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66; Other: laboratory biomarker analysis; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)

Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin; Drug: MK1775; Drug: MK1775; Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Radiation: CyberKnife Stereotactic Radiosurgery
Sponsors: Accuray Incorporated; Accuray Incorporated; University of Pittsburgh
Recruiting - verified February 2012
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Conditions: Solid Tumor; Adult Central Nervous System Germ Cell Tumor; Adult Rhabdomyosarcoma; Childhood Central Nervous System Germ Cell Tumor; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Ovarian Mixed Germ Cell Tumor; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma; Recurrent Childhood Visual Pathway Glioma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Neuroblastoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Wilms Tumor and Other Childhood Kidney Tumors; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: busulfan; Drug: melphalan; Drug: topotecan hydrochloride; Other: laboratory biomarker analysis; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation; Other: pharmacological study; Procedure: autologous bone marrow transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants

Condition: Ovarian Cancer
Intervention:
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified April 2012
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Conditions: Breast Cancer,; Advanced Solid Tumors,; Cowden Syndrome
Intervention: Drug: BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Carboplatin; Drug: nab-paclitaxel; Drug: trastuzumab
Sponsors: Brown University; Debora G. Isdale; Yale University
Recruiting - verified February 2012
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: ThermoDox; Drug: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified June 2011
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Liver Cancer; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

Condition: Dysphagia
Intervention: Device: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)
Sponsors: Boston Medical Center; Boston Medical Center; Northwestern University; Boston University; University of Wisconsin, Madison; New York University; VA Boston Healthcare System; Lahey Clinic; Lenox Hill Hospital; Beth Israel Medical Center; Greater Baltimore Medical Center; Medical College of Wisconsin; Community Medical Center, Inc; Henry Ford Hospital; University of California, San Diego; University of California, Davis; University of Washington; Oregon Health and Science University
Recruiting - verified June 2011
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study

Conditions: Head and Neck Cancer; Head and Neck Cancers
Intervention: Procedure: tumor biopsy
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

Condition: Breast Cancer
Intervention: Device: combined optical and MR imaging
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified August 2011
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Biological: autologous dendritic cell-adenovirus CCL21 vaccine
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI); Department of Veterans Affairs
Recruiting - verified February 2012
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Interventions: Drug: Nifurtimox; Drug: Cyclophosphamide; Drug: Topotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Bayer
Recruiting - verified April 2012
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Condition: Liver Cancer
Interventions: Radiation: brachytherapy; Radiation: yttrium Y 90 glass microspheres
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Early Onset and Familial Gastric Cancer Registry

Condition: Gastric Cancer
Intervention: Behavioral: questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Queens Health Network; USC/Norris Comprehensive Cancer Center; Shaare Zedek Medical Center; Obafemi Awolowo University Teaching Hospital; State University of New York - Downstate Medical Center
Recruiting - verified December 2011
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Condition: Prostate Cancer
Interventions: Behavioral: Questionaires; Behavioral: Questionaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); City of Hope National Medical Center; Fordham University; Columbia University; New York University Medical Center
Recruiting - verified March 2012
Trial of Aspirin and Arginine Restriction in Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Drug: Aspirin
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified March 2012
Study of Breast Cancer Prevention by Letrozole in High Risk Women

Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Placebo
Sponsors: University of Kansas; Carol Fabian, MD; Novartis; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2012
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample

Conditions: Breast Cancer; Stomach Neoplasms; Salivary Gland Neoplasms; Thyroid Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: celebrex (celecoxib); Drug: placebo capsules
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Condition: Non-small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Genentech
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: lapatinib ditosylate; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified July 2009
Intensity-Modulated Radiation Therapy, Fludarabine, and Melphalan Followed by a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer

Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: intensity-modulated radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Condition: Malignant Melanoma
Interventions: Drug: Peginterferon alpha-2b, non- pegylated interferon alpha-2b; Drug: Temozolomide, peginterferon alpha-2b
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Schering-Plough
Recruiting - verified January 2012
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma

Conditions: Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified July 2011
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Conditions: Gastroesophageal Junction Adenocarcinoma; Gastric Cancer
Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Sanofi-Aventis; Roche/Genetech; City of Hope National Medical Center; Piedmont Hospital Research Institute (PHRI); Medical College of Wisconsin; Queens Health Network; Weill Medical College of Cornell University; Memorial Cancer Institute, Florida; University of Pittsburgh; Long Island Jewish Medical Center; Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Recruiting - verified January 2012
Identification of Key Blood Molecular Markers for Immunotherapy

Conditions: Squamous Cell Carcinoma; Adenocarcinoma; Neoplasms
Intervention: Procedure: phlebotomy
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Condition: Metastatic Malignant Uveal Melanoma
Intervention: Drug: Marqibo® (vincristine sulfate liposomes injection)
Sponsors: Talon Therapeutics, Inc; Talon Therapeutics, Inc
Recruiting - verified September 2011
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Assessment Tool for Older Patients With Cancer

Conditions: Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Inflammatory Breast Cancer (IBC) Registry

Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Effect of Weight Loss on Prostate Cancer Pathology

Conditions: Obesity; Prostate Cancer
Interventions: Behavioral: Weight Loss; Other: No Weight Loss Group
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012
Abraxane and Alimta in Advanced Solid Tumors

Conditions: Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: pemetrexed disodium
Sponsors: University of California, Davis; University of California, Davis; National Cancer Institute (NCI)
Recruiting - verified May 2012
High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes

Condition: Melanoma
Intervention: Procedure: High-resolution contrast-enhanced MRI scan
Sponsors: Redwood Regional Medical Group; Redwood Regional Medical Group
Recruiting - verified July 2011
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide; Drug: sunitinib malate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified November 2011
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

Condition: Lung Cancer
Interventions: Procedure: computed tomography; Procedure: positron emission tomography; Radiation: fludeoxyglucose F 18
Sponsors: University of California, Los Angeles; University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified February 2012
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Biobank For MS And Other Demyelinating Diseases

Conditions: Multiple Sclerosis; Transverse Myelitis; Neuromyelitis Optica; Acute Disseminated Encephalomyelitis; Optic Neuritis
Intervention:
Sponsors: Accelerated Cure Project for Multiple Sclerosis; Accelerated Cure Project for Multiple Sclerosis
Recruiting - verified March 2012
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: autologous tumor cell vaccine; Biological: sargramostim; Biological: therapeutic autologous dendritic cells
Sponsors: National Cancer Institute (NCI); Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian
Recruiting - verified June 2009
Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: type of decision aid
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified November 2011
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Gliogene: Brain Tumor Linkage Study

Conditions: Brain Tumor; Glioma
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
E7389 and Cisplatin in Treating Patients With Advanced Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cisplatin; Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fenretinide; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Randomized Trial of Unruptured Brain AVMs

Condition: Unruptured Brain Arteriovenous Malformation
Intervention: Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors: Columbia University; Columbia University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011
Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

Conditions: Lymphedema; Breast Cancer
Intervention: Device: Flexitouch
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: physiologic testing; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified October 2006
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Quality of Life Following Radical Prostatectomy

Conditions: Prostatic Neoplasms; Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified May 2012
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Condition: Liver Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011
E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Characterization of the Melanoma-Specific Immune Response

Condition: Melanoma
Intervention:
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified June 2011
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: ex-vivo umbilical cord blood expansion; Procedure: double-unit umbilical cord blood transplantation; Procedure: biopsy; Other: immunologic technique; Other: diagnostic laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
PXD101 and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: belinostat
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer

Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer

Conditions: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Pain; Perioperative/Postoperative Complications; Sarcoma
Interventions: Drug: fentanyl citrate; Drug: hydromorphone hydrochloride; Drug: ropivacaine hydrochloride
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified September 2007
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer

Condition: Prostate Cancer
Intervention: Device: hybrid PET-CT imaging system
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: amifostine trihydrate; Procedure: peripheral blood stem cell transplantation; Genetic: fluorescence in situ hybridization; Procedure: bone marrow ablation with stem cell support
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Microarray Analysis of Gene Expression in Prostate Tissues

Condition: Prostate Cancer
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

Condition: Renal Cell Cancer
Interventions: Drug: Bevacizumab and Bortezomib; Drug: Bevacizumab and Bortezomib
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Conditions: Myeloproliferative Disorders; Blood Cancer; Myelodysplastic Syndromes
Interventions: Procedure: Total Lymphoid Irradiation (TLI); Procedure: Anti-Thymocyte Globulin as Conditioning
Sponsors: Stanford University; Stanford University; National Institutes of Health (NIH)
Recruiting - verified January 2012
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma

Conditions: Testicular Cancer; Germ Cell Neoplasm
Intervention: Drug: paclitaxel, gemcitabine, and oxaliplatin
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Sanofi-Aventis
Recruiting - verified May 2012
A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Condition: Sarcoma
Intervention: Drug: Trabectedin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Drug: celecoxib
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: lomustine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Hospital of Philadelphia
Recruiting - verified June 2009
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: buthionine sulfoximine; Drug: melphalan; Procedure: Peripheral blood stem cell infusion; Other: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phenotype and Etiology of Pallister-Hall Syndrome

Conditions: Malformations; Multiple Abnormalies; Polydactyly
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified April 2012